Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universal Health International Group Holding (HKSE:02211) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Universal Health International Group Holding ROCE % Related Terms
Universal Health International Group Holding ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universal Health International Group Holding ROCE % Chart
Universal Health International Group Holding Annual Data
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universal Health International Group Holding (HKSE:02211) has a ROCE % of -2.80% as of Dec. 2025.
Is Universal Health International Group Holding's ROCE % too high?
Universal Health International Group Holding's current ROCE % is -2.80%. Overall, Universal Health International Group Holding has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Universal Health International Group Holding's ROCE % compare to competitors?
Universal Health International Group Holding's ROCE % of -2.80% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.32, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universal Health International Group Holding's current ROCE % is -2.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Health International Group Holding stock overvalued right now?
Based on GuruFocus' analysis, Universal Health International Group Holding (HKSE:02211) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.66 — trading 125.9% above its estimated fair value. The current ROCE % is -2.80%. Universal Health International Group Holding's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Universal Health International Group Holding (HKSE:02211), the current ROCE % is -2.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universal Health International Group Holding (HKSE:02211) Overvalued in 2026?
Based on GuruFocus' analysis, Universal Health International Group Holding stock appears to be overvalued.
The current stock price of HK$0.66 is trading 125.9% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Universal Health International Group Holding to be Significantly Overvalued.
Key valuation signals for HKSE:02211:
ROCE %: -2.80%
GF Value™: HK$0.29 vs. price of HK$0.66 (125.9% above fair value)
No single metric tells the full story. See the HKSE:02211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universal Health International Group Holding Ltd distributes and retails pharmaceutical products in Northeast China. The company operates its business through two segments: pharmaceutical retail and Distribution, (including import and export trade) include prescribed drugs, non-prescribed drugs (Chinese patent medicines, chemical preparations, antibiotics and biochemical drugs), traditional Chinese medicine decoction pieces, biological products, protein assimilation preparations, peptide hormones, blood products, disinfection products, medical equipment, etc. and majority of revnue comes from Distribution segment.
37GF Score
Get the complete analysis for HKSE:02211
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02211 has been successfully added to your 
